Anti-IL-1α antibody vilamakitug meets primary endpoint in refractory metastatic colorectal cancer

▸ TREATMENT

In the phase 2 TASKIN trial, 61.3% of patients receiving vilamakitug plus standard-of-care therapy were alive at 12 months compared with 55.7% in the control arm, meeting the prespecified efficacy criterion. (Targeted Oncology)